CyberKnife Radiotherapy for the Treatment of Schwannomas

Overview

Historically, the management of schwannomas has relied primarily on observation, surgery, or conventional radiotherapy techniques. However, while surgery is curative, it carries significant risks-including postoperative complications, neurological deficits, and substantial morbidity-particularly for intracranial schwannomas located near critical neurovascular structures. Stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT) has emerged as a less invasive alternative, offering remarkable precision in targeting tumor tissue while sparing adjacent healthy structures. This technique employs high doses of radiation focused precisely on the tumor, thereby controlling tumor growth with minimal morbidity. Several studies have demonstrated that SRS is particularly effective for small- to medium-sized schwannomas, yielding high tumor control rates (exceeding 90% at 5 years) while preserving neurological function. Despite this, the natural history, clinical data, and post-treatment outcomes associated with schwannomas remain incompletely understood or not fully elucidated in scientific literature.

Schwannomas are benign tumors arising from Schwann cells in the peripheral nervous system; the most common type is the vestibular schwannoma (also known as an acoustic neuroma). Although these tumors are non-malignant, their location-particularly on cranial or spinal nerves-can lead to serious complications such as hearing loss, balance disorders, and neurological dysfunction. Treatment aims to prevent tumor growth and preserve neurological function. The natural history, clinical data, and post-treatment outcomes of schwannomas remain incomplete or not fully elucidated. Stereotactic radiosurgery (SRS) has emerged as a less invasive alternative, offering remarkable precision in targeting tumor tissue while sparing adjacent healthy structures. This technique employs high doses of radiation focused precisely on the tumor, thereby controlling tumor growth with minimal morbidity. Several studies have demonstrated that SRS is particularly effective for small- to medium-sized schwannomas, yielding high tumor control rates (exceeding 90% at 5 years) while preserving neurological function. Despite this, the natural history, clinical data, and post-treatment outcomes associated with schwannomas remain incompletely understood or not fully elucidated in scientific literature. Real-world data enables a better understanding of diseases, the optimization of care pathways, and the acceleration of the development of new treatments or personalized diagnostics.